Showcasing the Depth of Immunology Portfolio and Pipeline

AbbVie to present 38 abstracts highlighting our commitment to advancing the standard of care for patients with rheumatic diseases at the 2019 ACR/ARP Annual Meeting.

Read more

Our journey of impact

Come with us as we remember where we’ve been, and look forward to where we’re going.

Learn more

Latest news

If you are a member of the news media and have questions or need additional information, please contact our communications team.

Nov 08, 2019

AbbVie Submits Supplemental New Drug Application to U.S. FDA For IMBRUVICA® (ibrutinib) in Combination with Rituximab for the Treatment of Previously Untreated, Younger Adults with Chronic Lymphocytic Leukemia

Nov 07, 2019

AbbVie Announces Results of Early Participation in Exchange Offers and Consent Solicitations for Allergan Notes

Nov 06, 2019

AbbVie Announces Launch of Private Offering of Senior Unsecured Notes

Nov 04, 2019

AbbVie to Showcase Depth of Immunology Portfolio and Pipeline at the 2019 ACR/ARP Annual Meeting
Read More

You must be logged in to view this item.

This area is reserved for members of the news media. If you qualify, please update your user profile and check the box marked "Check here to register as an accredited member of the news media". Please include any notes in the "Supporting information for media credentials" box. We will notify you of your status via e-mail in one business day.

YOU ARE ABOUT TO LEAVE FOR A 3RD PARTY WEBSITE

Notice

The "Yes" link below will take you out of the AbbVie family of websites.

Links which take you out of the AbbVie worldwide websites are not under the control of AbbVie, and AbbVie is not responsible for the contents of any such site or any further links from such site. AbbVie is providing these links to you only as a convenience and the inclusion of any link does not imply endorsement of the linked site by AbbVie.

The Internet site that you have requested may not be optimized to your screen size.

Do you wish to leave this site?